Circe Biomedical
Circe Biomedical, Inc. develops bioartificial liver assist devices for acute, end-stage liver failure treatment in the US.
Founded
1999Circe Biomedical, Inc. develops bioartificial liver assist devices for acute, end-stage liver failure treatment in the US.
Founded with a mission to revolutionize liver failure treatment, Circe Biomedical, Inc. focuses on developing advanced medical devices. Their flagship product is a bioartificial liver assist device designed to support patients suffering from acute, end-stage liver failure. By leveraging cutting-edge biomedical technology, Circe Biomedical aims to provide innovative solutions that enhance patient outcomes and address critical needs within the United States healthcare industry.
Circe Biomedical has garnered attention from notable figures in the medical and investment communities, contributing to its growing reputation. The company has achieved significant milestones in the development and clinical testing of its bioartificial liver assist device, positioning itself as a leader in the field of liver support systems. Through its pioneering work, Circe Biomedical is making a substantial impact on the treatment landscape for liver failure, offering new hope to patients and healthcare providers alike.
Companies similar to Circe Biomedical include Circle Biologics, Halcyon Biomedical, BiomedInnovations and Cirtec Medical.
Circe Biomedical was founded in 1999.
Circe Biomedical's headquarters is located in Lexington, MA, US.
Circe Biomedical's most recent funding round was for $28M (USD) in December 2000.
As of Dec 18, 2000, Circe Biomedical has disclosed funding of $28M (USD). Undisclosed round amounts are excluded.
Circe Biomedical has 30 employees as of Feb 5, 2024.
cirtecmed.com
